Cargando…

Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain

BACKGROUND: Iron deficiency anemia (IDA) is a common complication of inflammatory bowel disease (IBD) and can result in reduced quality of life and increased healthcare costs. IDA is treated with iron supplementation, commonly with intravenous iron formulations, such as ferric carboxymaltose (FCM),...

Descripción completa

Detalles Bibliográficos
Autores principales: Argüelles-Arias, Federico, Bermejo, Fernando, Borrás-Blasco, Joaquín, Domènech, Eugeni, Sicilia, Beatriz, Huguet, José M., de Arellano, Antonio Ramirez, Valentine, William J., Hunt, Barnaby
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092579/
https://www.ncbi.nlm.nih.gov/pubmed/35574429
http://dx.doi.org/10.1177/17562848221086131
_version_ 1784705166386135040
author Argüelles-Arias, Federico
Bermejo, Fernando
Borrás-Blasco, Joaquín
Domènech, Eugeni
Sicilia, Beatriz
Huguet, José M.
de Arellano, Antonio Ramirez
Valentine, William J.
Hunt, Barnaby
author_facet Argüelles-Arias, Federico
Bermejo, Fernando
Borrás-Blasco, Joaquín
Domènech, Eugeni
Sicilia, Beatriz
Huguet, José M.
de Arellano, Antonio Ramirez
Valentine, William J.
Hunt, Barnaby
author_sort Argüelles-Arias, Federico
collection PubMed
description BACKGROUND: Iron deficiency anemia (IDA) is a common complication of inflammatory bowel disease (IBD) and can result in reduced quality of life and increased healthcare costs. IDA is treated with iron supplementation, commonly with intravenous iron formulations, such as ferric carboxymaltose (FCM), and iron sucrose (IS). METHODS: This study assessed the cost-effectiveness of FCM compared with IS, in terms of additional cost per additional responder in patients with IDA subsequent to IBD in the Spanish setting. An economic model was developed to assess the additional cost per additional responder, defined as normalization or an increase of ⩾2 g/dl in hemoglobin levels, for FCM versus IS from a Spanish healthcare payer perspective. Efficacy inputs were taken from a randomized controlled trial comparing the two interventions (FERGIcor). Costs of treatment were calculated in 2021 Euros (EUR) using a microcosting approach and included the costs of intravenous iron, healthcare professional time, and consumables. Cost-effectiveness was assessed over one cycle of treatment, with a series of sensitivity analyses performed to test the robustness of the results. RESULTS: FCM was more effective than IS, with 84% of patients achieving a response compared with 76%. When expressed as number needed to treat, 13 patients would need to switch treatment from IS to FCM in order to achieve one additional responder. Costs of treatment were EUR 323 with FCM compared with EUR 470 with IS, a cost saving of EUR 147 with FCM. Cost savings with FCM were driven by the reduced number of infusions required, resulting in a reduced requirement for healthcare professional time and use of consumables compared with the IS arm. CONCLUSION: The present analysis suggests that FCM is less costly and more effective than IS for the treatment of IDA subsequent to IBD in Spain and therefore was considered dominant.
format Online
Article
Text
id pubmed-9092579
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-90925792022-05-12 Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain Argüelles-Arias, Federico Bermejo, Fernando Borrás-Blasco, Joaquín Domènech, Eugeni Sicilia, Beatriz Huguet, José M. de Arellano, Antonio Ramirez Valentine, William J. Hunt, Barnaby Therap Adv Gastroenterol Original Research BACKGROUND: Iron deficiency anemia (IDA) is a common complication of inflammatory bowel disease (IBD) and can result in reduced quality of life and increased healthcare costs. IDA is treated with iron supplementation, commonly with intravenous iron formulations, such as ferric carboxymaltose (FCM), and iron sucrose (IS). METHODS: This study assessed the cost-effectiveness of FCM compared with IS, in terms of additional cost per additional responder in patients with IDA subsequent to IBD in the Spanish setting. An economic model was developed to assess the additional cost per additional responder, defined as normalization or an increase of ⩾2 g/dl in hemoglobin levels, for FCM versus IS from a Spanish healthcare payer perspective. Efficacy inputs were taken from a randomized controlled trial comparing the two interventions (FERGIcor). Costs of treatment were calculated in 2021 Euros (EUR) using a microcosting approach and included the costs of intravenous iron, healthcare professional time, and consumables. Cost-effectiveness was assessed over one cycle of treatment, with a series of sensitivity analyses performed to test the robustness of the results. RESULTS: FCM was more effective than IS, with 84% of patients achieving a response compared with 76%. When expressed as number needed to treat, 13 patients would need to switch treatment from IS to FCM in order to achieve one additional responder. Costs of treatment were EUR 323 with FCM compared with EUR 470 with IS, a cost saving of EUR 147 with FCM. Cost savings with FCM were driven by the reduced number of infusions required, resulting in a reduced requirement for healthcare professional time and use of consumables compared with the IS arm. CONCLUSION: The present analysis suggests that FCM is less costly and more effective than IS for the treatment of IDA subsequent to IBD in Spain and therefore was considered dominant. SAGE Publications 2022-05-09 /pmc/articles/PMC9092579/ /pubmed/35574429 http://dx.doi.org/10.1177/17562848221086131 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Argüelles-Arias, Federico
Bermejo, Fernando
Borrás-Blasco, Joaquín
Domènech, Eugeni
Sicilia, Beatriz
Huguet, José M.
de Arellano, Antonio Ramirez
Valentine, William J.
Hunt, Barnaby
Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain
title Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain
title_full Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain
title_fullStr Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain
title_full_unstemmed Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain
title_short Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain
title_sort cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in spain
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092579/
https://www.ncbi.nlm.nih.gov/pubmed/35574429
http://dx.doi.org/10.1177/17562848221086131
work_keys_str_mv AT arguellesariasfederico costeffectivenessanalysisofferriccarboxymaltoseversusironsucroseforthetreatmentofirondeficiencyanemiainpatientswithinflammatoryboweldiseaseinspain
AT bermejofernando costeffectivenessanalysisofferriccarboxymaltoseversusironsucroseforthetreatmentofirondeficiencyanemiainpatientswithinflammatoryboweldiseaseinspain
AT borrasblascojoaquin costeffectivenessanalysisofferriccarboxymaltoseversusironsucroseforthetreatmentofirondeficiencyanemiainpatientswithinflammatoryboweldiseaseinspain
AT domenecheugeni costeffectivenessanalysisofferriccarboxymaltoseversusironsucroseforthetreatmentofirondeficiencyanemiainpatientswithinflammatoryboweldiseaseinspain
AT siciliabeatriz costeffectivenessanalysisofferriccarboxymaltoseversusironsucroseforthetreatmentofirondeficiencyanemiainpatientswithinflammatoryboweldiseaseinspain
AT huguetjosem costeffectivenessanalysisofferriccarboxymaltoseversusironsucroseforthetreatmentofirondeficiencyanemiainpatientswithinflammatoryboweldiseaseinspain
AT dearellanoantonioramirez costeffectivenessanalysisofferriccarboxymaltoseversusironsucroseforthetreatmentofirondeficiencyanemiainpatientswithinflammatoryboweldiseaseinspain
AT valentinewilliamj costeffectivenessanalysisofferriccarboxymaltoseversusironsucroseforthetreatmentofirondeficiencyanemiainpatientswithinflammatoryboweldiseaseinspain
AT huntbarnaby costeffectivenessanalysisofferriccarboxymaltoseversusironsucroseforthetreatmentofirondeficiencyanemiainpatientswithinflammatoryboweldiseaseinspain